Scientific background: Uncontrolled gestational diabetes mellitus (GDM) is associated with severe maternal and neonatal morbidities. Treatment of GDM is multidisciplinary and includes lifestyle changes and medications. However, the efficacy of these treatments is limited due to poor motivation, daily painful blood tests and multiple injections. Probiotic supplements were shown to modulate the gut microbiome by reducing the adverse metabolic effects associated with pathogenic microbial colonization. Promising effects on glycemic control and insulin resistance in non-pregnant diabetic patients were reported. However, the effect of probiotics on glycemic control in GDM has not been elucidated. Objectives: To examine the effect of a mixture of probiotic strains given daily on maternal glycemic parameters, and pregnancy outcomes among women with GDM. Working hypothesis: Oral administration of probiotics will be effective in glucose control of patients with GDM and their neonates without causing significant adverse effects. Type of research and methods of data collection: A prospective randomized, double blind, placebo controlled trial. Women newly diagnosed with GDM will be recruited and followed in the GDM clinic and Maternal-Fetal Medicine ward (including the research clinic) at Emek Medical Center. They will be divided into a research group, receiving the probiotic formula Femina II and a control group, receiving a placebo (2 capsules/day) until delivery. Glycemic control will be evaluated by daily glucose charts. After 2 weeks of diet and probiotic/placebo treatment and thereafter, pharmacotherapy will be started in case of poor glycemic control according to the daily glucose charts. Blood tests for glycated molecules will be performed. Fetal well-being and growth will be assessed. The primary outcomes are: 1. The rate of women requiring medications for glycemic control 2. Mean value of the mean daily glucose charts after 2 weeks of treatment with the study products.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
93
Assuta-Ashdod medical center
Ashdod, Israel
Rambam medical center
Haifa, Israel
Wolfson medical center
Holon, Israel
Poriya Medical center
Tiberias, Israel
The rate of women who will require pharmacotherapy for glycemic control.
Time frame: During the length of pregnancy (up to 9 months)
Mean value of the mean daily glucose charts after 2 weeks of treatment with the study products.
Time frame: 2 weeks
The rate of women with controlled diabetes
Time frame: During the length of pregnancy (up to 9 months)
Mean daily glucose charts
Time frame: During the length of pregnancy (up to 9 months)
Mean daily pre-prandial glucose values
Time frame: During the length of pregnancy (up to 9 months)
Mean daily post-prandial glucose values
Time frame: During the length of pregnancy (up to 9 months)
Level of glycated molecules
Time frame: During the length of pregnancy (up to 9 months)
The rate of women with mean pre-prandial values ≥ 95 mg/dl, mean post-prandial values ≥ 130 mg/dl, and mean daily glucose > 100 mg/dl
Time frame: During the length of pregnancy (up to 9 months)
The rate of cesarean deliveries
Time frame: At delivery
The rate of labor inductions
Time frame: At delivery
The rate of birth weight≥4000 gr
Time frame: At delivery
The rate of birth weight> 90th percentile
Time frame: At delivery
The rate of admission to the neonatal intensive care unit
Time frame: Within a week from delivery
Apgar score at 1 and 5 minutes from birth
Time frame: Within 1-5 minutes after delivery
The rate of neonatal hypoglycemia
Time frame: Within 1-2 days after delivery
The rate of neonatal hyperbilirubinemia
Time frame: Within a week from delivery
The rate of neonatal polycythemia
Time frame: Within a week from delivery
The rate of neonatal hypocalcemia
Time frame: Within a week from delivery
The rate of neonatal hypomagnesemia
Time frame: Within a week from delivery
Cord blood pH levels
Time frame: At delivery
The rate of neonatal malformations and developmental disorders
Time frame: 1-2 days after delivery
birth weight
Time frame: At delivery
Head circumference
Time frame: 1-2 days after delivery
Maternal adverse effects
Time frame: During the length of pregnancy (up to 9 months)
Duration of time until pharmacotherapy for glycemic control is indicated
Time frame: During the length of pregnancy (up to 9 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.